Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up – Here’s Why

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) shares gapped up before the market opened on Monday. The stock had previously closed at $13.38, but opened at $14.20. Alpha Tau Medical shares last traded at $12.4850, with a volume of 562,008 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DRTS. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, October 20th. Barclays lifted their price target on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Thursday, October 15th. Finally, Piper Sandler upgraded Alpha Tau Medical from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $8.00 to $22.00 in a report on Wednesday, November 11th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.20.

Get Our Latest Stock Report on Alpha Tau Medical

Alpha Tau Medical Trading Down 8.8%

The business has a 50 day moving average of $14.06 and a two-hundred day moving average of $10.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.68 and a beta of 1.28.

Insider Buying and Selling

In other news, CFO Raphi Levy sold 2,871 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the sale, the chief financial officer owned 90,180 shares in the company, valued at $1,352,700. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company’s stock.

Hedge Funds Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in Alpha Tau Medical in the 1st quarter valued at $286,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical during the 1st quarter valued at $132,000. Finally, Everhart Financial Group Inc. bought a new stake in Alpha Tau Medical during the 2nd quarter valued at $126,000. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

Further Reading

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.